Generic Medicine Info
Indications and Dosage
Advanced breast cancer in postmenopausal women
Adult: 250 mg every 2 wk into each buttock alternately.
Women with premenopausal endocrine status, pregnancy, lactation.
Special Precautions
Avoid unintentional intravascular inj or inj into or near the sciatic nerve. Do not inject into areas with resistance or showing inflammation from previous admin. Monitor blood glucose in diabetics. Caution if driving or operating machinery.
Adverse Reactions
Local irritation and pain at the site of inj, hot flushes, rashes, drowsiness, dizziness, emotional lability, oedema of the leg, thrombophloebitis, vaginal spotting or bleeding, GI disturbances, muscle cramps, arthralgia and vasovagal reaction.
Description: Formestane has anti-oestrogenic properties as seen in the inhibition of the oestrogen synthetase (aromatase) system which is essential in the production of oestrogens from androgens.
Distribution: About 85% bound to plasma proteins.
Metabolism: Metabolised by conjugation to the inactive glucuronide.
Excretion: Apparent elimination half-life: 5-6 days. <1% of the dose is excreted unchanged in urine.
MIMS Class
Cancer Hormone Therapy
Disclaimer: This information is independently developed by MIMS based on Formestane from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in